Opdivo + Yervoy combination could be an alternative to ‘Extreme’ chemotherapy in some head and neck cancers.
The immunotherapies nivolumab and ipilimumab from Bristol Myers Squibb, helped some patients with advanced head and neck cancer live longer, compared with ‘Extreme’ standard treatment consisting of an aggressive cocktail of two chemotherapy drugs and a targeted antibody treatment (comprised of cetuximab (Erbitux), cisplatin/carboplatin, and fluorouracil). The results were not statistically significant, but the immunotherapy combination, designed to spark the immune system into action against cancer, led to a positive trend in survival when compared to the ‘Extreme’ standard in a group of patients - those with tumours that had high levels of an immune marker called PD-L1.
In fact, survival rates for patients with high levels of PD-L1 who received the immunotherapy combination were the highest ever reported in a first-line therapy trial of relapsed or metastatic head and neck cancer.
Related news and insights
Genentech, a member of the Roche Group announced that the FDA has accepted the company’s Biologics License Application (BLA) and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies.
Novavax, Inc. announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) for adolescents aged 12 through 17.
NICE (UK) (National Institute for Care and Health Excellence): Pembrolizumab plus chemotherapy (paclitaxel or nab-paclitaxel) is recommended as an option for treating triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.